A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Genentech

Status and phase

Completed

Phase 1

Conditions

Non-Hodgkin's Lymphoma, Solid Cancers

Treatments

Drug: GDC-0980

Study type

Interventional

Funder types

Industry

Identifiers

NCT00854152

PIM4604g

MP00880 (Other Identifier)

Details and patient eligibility

About

This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy.

Enrollment

121 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically documented, incurable, locally advanced or metastatic solid malignancies, or NHL without leukemic phase, that has progressed despite standard of care therapy or for which there is no standard therapy of proven clinical benefit
ECOG performance status of 0 or 1 at screening
Evaluable or measurable disease per RECIST and/or the following: prostate cancer patients with non-measurable disease are eligible if they have two rising prostate-specific antigen (PSA) levels that meet the PSA Working Group criteria for progression prior to initiation of study treatment; ovarian cancer patients with non-measurable disease are eligible if they have two rising CA-125 levels greater than the ULN >= 2 weeks apart prior to initiation of study treatment.
Life expectancy >=12 weeks
Adequate hematologic and organ function within 14 days before initiation of GDC-0980
Documented willingness to use an effective means of contraception for both men and women while participating in the study

Exclusion criteria

Leptomeningeal disease as the only manifestation of the current malignancy
History of Type 1 or 2 diabetes mellitus requiring regular medication
Grade >= 2 hypercholesterolemia or hypertriglyceridemia
Ejection fraction that is <50% or below the LLN (whichever is higher), as determined by echocardiogram or MUGA scan
DLCO < 50% of predicted value corrected for hemoglobin and alveolar volume prior to initiation of GDC-0980
Malabsorption syndrome or other condition that would interfere with enteral absorption
Known untreated malignancies of the brain or spinal cord, or treated brain metastases that are not radiographically stable for >= 3 months
Active congestive heart failure or ventricular arrhythmia requiring medication
Active infection requiring IV antibiotics
Requirement for any daily supplemental oxygen
Uncontrolled hypomagnesemia
Hypercalcemia requiring continued use of bisphosphonate therapy
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
Uncontrolled ascites requiring frequent paracentesis
Known HIV infection
Any other diseases, active or controlled pulmonary dysfunction, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug
Significant traumatic injury within 4 weeks of Day 1
Major surgical procedure within 4 weeks prior to initiation of GDC-0980
For all patients participating in Stage 2: Prior treatment with any PI3K inhibitor, mTOR inhibitor or dual PI3K/mTOR inhibitor. For HNSCC patients, this restriction applies only to any PI3K inhibitor, mTOR inhibitor, or dual PI3K/mTOR inhibitor used in the palliative setting.
Treatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives, or GnRH agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within 3 weeks prior to initiation of GDC-0980
Palliative radiation to bony metastases within 2 weeks prior to initiation of GDC-0980
Need for chronic corticosteroid therapy of >= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressant
Treatment with an investigational agent within 4 weeks prior to initiation of GDC-0980
Unresolved toxicity from prior therapy except for alopecia and Grade 1 peripheral neuropathy
Pregnancy or lactation
For patients participating in DCE-MRI assessments, any contraindication to MRI examination
For patients with advanced solid tumors or NHL participating in the PPI-effect assessment: Known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation